De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Zoetis Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Zoetis is de winst gegroeid met een gemiddeld jaarlijks percentage van 10.3%, terwijl de Pharmaceuticals industrie de winst daalde met 0.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 7.9% per jaar. Het rendement op eigen vermogen van Zoetis is 47.2%, en het heeft een nettomarge van 26.3%.
Belangrijke informatie
10.3%
Groei van de winst
11.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | 7.9% |
| Rendement op eigen vermogen | 47.2% |
| Nettomarge | 26.3% |
| Volgende winstupdate | 04 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Zoetis: Investing In Pet Health And Portfolio Wealth
Sep 26Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?
Sep 20
There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price
Aug 30Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target
Aug 13Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)
Aug 07Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Jul 16Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price
Jul 03Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader
Jun 11A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Jun 10Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth
May 23Zoetis: Why The Focus On Companion Animal Segment Will Pay Off
May 22The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 04Zoetis: Long-Term Buy Despite Safety Concerns
May 03Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment
Apr 15Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit
Apr 12Zoetis: My Favorite Healthcare Stock Right Now
Mar 21Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
Mar 03Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness
Feb 27Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns
Jan 10Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E
Jan 01Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Dec 14Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Dec 06Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today
Nov 18Zoetis: High-Quality Compounder With A Reasonable Price After Earnings
Nov 09Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now
Oct 26Zoetis Is An Impressive Healthcare Compounder
Sep 26Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Sep 25Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly
Sep 04Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.
Aug 22Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?
Aug 12Zoetis: My Dog Approves Of This Dividend Compounder
Jul 19Zoetis: A Purrfect Addition To Your Portfolio
Jun 22Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?
Jun 10These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well
Apr 16Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Mar 10Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus
Feb 14Zoetis Is An Awesome Dividend Growth Stock
Jan 17It's A Great Time To Buy Zoetis Shares
Jan 10Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Jan 03Is Zoetis (NYSE:ZTS) Using Too Much Debt?
Dec 29Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Dec 14Opbrengsten en kosten
Hoe Zoetis geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 8,915 | 2,344 | 2,218 | 659 |
| 31 Mar 24 | 8,734 | 2,391 | 2,193 | 634 |
| 31 Dec 23 | 8,544 | 2,344 | 2,151 | 614 |
| 30 Sep 23 | 8,371 | 2,280 | 2,100 | 588 |
| 30 Jun 23 | 8,222 | 2,213 | 2,076 | 570 |
| 31 Mar 23 | 8,094 | 2,071 | 2,049 | 559 |
| 31 Dec 22 | 8,080 | 2,114 | 2,009 | 539 |
| 30 Sep 22 | 8,007 | 2,067 | 2,088 | 529 |
| 30 Jun 22 | 7,995 | 2,090 | 2,091 | 527 |
| 31 Mar 22 | 7,891 | 2,073 | 2,057 | 512 |
| 31 Dec 21 | 7,776 | 2,037 | 2,001 | 508 |
| 30 Sep 21 | 7,616 | 1,982 | 1,926 | 503 |
| 30 Jun 21 | 7,412 | 1,909 | 1,841 | 483 |
| 31 Mar 21 | 7,012 | 1,774 | 1,734 | 474 |
| 31 Dec 20 | 6,675 | 1,638 | 1,713 | 463 |
| 30 Sep 20 | 6,542 | 1,663 | 1,665 | 462 |
| 30 Jun 20 | 6,340 | 1,617 | 1,637 | 462 |
| 31 Mar 20 | 6,339 | 1,611 | 1,655 | 462 |
| 31 Dec 19 | 6,260 | 1,500 | 1,636 | 457 |
| 30 Sep 19 | 6,150 | 1,461 | 1,553 | 450 |
| 30 Jun 19 | 6,046 | 1,375 | 1,529 | 446 |
| 31 Mar 19 | 5,914 | 1,388 | 1,482 | 437 |
| 31 Dec 18 | 5,825 | 1,428 | 1,482 | 432 |
| 30 Sep 18 | 5,721 | 1,164 | 1,424 | 417 |
| 30 Jun 18 | 5,588 | 1,115 | 1,386 | 405 |
| 31 Mar 18 | 5,442 | 978 | 1,362 | 389 |
| 31 Dec 17 | 5,307 | 864 | 1,325 | 382 |
| 01 Oct 17 | 5,124 | 937 | 1,320 | 380 |
| 02 Jul 17 | 5,018 | 878 | 1,325 | 374 |
| 02 Apr 17 | 4,957 | 855 | 1,323 | 376 |
| 31 Dec 16 | 4,888 | 821 | 1,316 | 376 |
| 02 Oct 16 | 4,885 | 689 | 1,362 | 375 |
| 03 Jul 16 | 4,858 | 639 | 1,374 | 376 |
| 03 Apr 16 | 4,825 | 378 | 1,383 | 372 |
| 31 Dec 15 | 4,765 | 339 | 1,402 | 362 |
| 27 Sep 15 | 4,811 | 443 | 1,464 | 378 |
| 28 Jun 15 | 4,807 | 420 | 1,483 | 380 |
| 29 Mar 15 | 4,790 | 593 | 1,506 | 388 |
| 31 Dec 14 | 4,785 | 583 | 1,512 | 396 |
| 28 Sep 14 | 4,719 | 562 | 1,461 | 391 |
| 29 Jun 14 | 4,612 | 527 | 1,455 | 390 |
| 30 Mar 14 | 4,568 | 519 | 1,429 | 389 |
| 31 Dec 13 | 4,561 | 504 | 1,428 | 392 |
Kwaliteitswinsten: ZTS heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (26.3%) ZTS } zijn lager dan vorig jaar (26.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van ZTS is de afgelopen 5 jaar met 10.3% per jaar gegroeid.
Versnelling van de groei: De winstgroei van ZTS over het afgelopen jaar ( 5.9% ) ligt onder het 5-jarig gemiddelde ( 10.3% per jaar).
Winst versus industrie: De winstgroei ZTS over het afgelopen jaar ( 5.9% ) overtrof de Pharmaceuticals -sector 13%.
Rendement op eigen vermogen
Hoge ROE: Hoewel het rendement op eigen vermogen ( 47.22% ) van ZTS uitstekend is, is deze metriek vertekend vanwege hun hoge schuldenniveau.